D. E. Shaw & Co., Inc. Ironwood Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 384,949 shares of IRWD stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

384,949

Previous 288,653 33.36%

Holding current value

$1.79 Million

Previous $2.51 Million 0.2%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.58 - $8.61 $537,331 - $829,108	96,296 Added 33.36%	384,949 $2.51 Million
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $496,063 - $921,175	59,623 Added 26.03%	288,653 $2.51 Million
Q4 2023 Feb 14, 2024	SELL	$8.79 - $11.51 $1.82 Million - $2.39 Million	-207,233 Reduced 47.5%	229,030 $2.62 Million
Q3 2023 Nov 14, 2023	SELL	$8.25 - $11.35 $3.98 Million - $5.48 Million	-482,735 Reduced 52.53%	436,263 $4.2 Million
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $1.19 Million - $1.37 Million	118,275 Added 14.77%	918,998 $9.78 Million
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $1.8 Million - $2.18 Million	173,337 Added 27.63%	800,723 $8.42 Million
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $692,524 - $869,503	69,952 Added 12.55%	627,386 $7.77 Million
Q3 2022 Nov 14, 2022	SELL	$10.14 - $12.38 $1.97 Million - $2.4 Million	-193,995 Reduced 25.82%	557,434 $5.78 Million
Q2 2022 Aug 15, 2022	SELL	$11.05 - $12.72 $4.81 Million - $5.53 Million	-434,953 Reduced 36.66%	751,429 $8.66 Million
Q1 2022 May 16, 2022	BUY	$10.61 - $12.88 $3.21 Million - $3.89 Million	302,288 Added 34.19%	1,186,382 $14.9 Million
Q4 2021 Feb 14, 2022	SELL	$10.86 - $13.95 $4.79 Million - $6.16 Million	-441,333 Reduced 33.3%	884,094 $10.3 Million
Q3 2021 Nov 15, 2021	BUY	$11.92 - $13.92 $4.07 Million - $4.75 Million	341,189 Added 34.67%	1,325,427 $17.3 Million
Q2 2021 Aug 16, 2021	SELL	$10.16 - $13.11 $5.45 Million - $7.04 Million	-536,802 Reduced 35.29%	984,238 $12.7 Million
Q1 2021 May 17, 2021	SELL	$9.04 - $11.86 $5.59 Million - $7.33 Million	-618,187 Reduced 28.9%	1,521,040 $17 Million
Q4 2020 Feb 16, 2021	BUY	$9.05 - $12.2 $2.63 Million - $3.55 Million	290,922 Added 15.74%	2,139,227 $24.4 Million
Q3 2020 Nov 16, 2020	BUY	$8.99 - $10.74 $1.21 Million - $1.44 Million	134,118 Added 7.82%	1,848,305 $16.6 Million
Q2 2020 Aug 14, 2020	BUY	$9.14 - $11.97 $414,937 - $543,414	45,398 Added 2.72%	1,714,187 $17.7 Million
Q1 2020 May 15, 2020	BUY	$8.58 - $14.01 $1.74 Million - $2.85 Million	203,163 Added 13.86%	1,668,789 $16.8 Million
Q4 2019 Feb 14, 2020	BUY	$8.22 - $14.0 $6.55 Million - $11.2 Million	797,330 Added 119.31%	1,465,626 $19.5 Million
Q3 2019 Nov 14, 2019	BUY	$8.59 - $10.96 $265,791 - $339,124	30,942 Added 4.85%	668,296 $5.74 Million
Q2 2019 Aug 14, 2019	SELL	$9.8 - $12.89 $3.43 Million - $4.51 Million	-350,178 Reduced 35.46%	637,354 $6.97 Million
Q1 2019 May 15, 2019	BUY	$8.27 - $12.73 $2.22 Million - $3.41 Million	268,090 Added 37.26%	987,532 $13.4 Million
Q4 2018 Feb 14, 2019	BUY	$7.8 - $16.13 $3.74 Million - $7.73 Million	479,462 Added 199.79%	719,442 $7.45 Million
Q3 2018 Nov 14, 2018	BUY	$14.31 - $17.65 $1.79 Million - $2.21 Million	125,171 Added 109.03%	239,980 $4.43 Million
Q2 2018 Aug 14, 2018	SELL	$11.83 - $16.2 $680,946 - $932,488	-57,561 Reduced 33.39%	114,809 $2.2 Million
Q1 2018 May 15, 2018	SELL	$11.13 - $13.63 $1.62 Million - $1.98 Million	-145,231 Reduced 45.73%	172,370 $2.66 Million
Q4 2017 Feb 14, 2018	BUY	$12.16 - $14.58 $313,047 - $375,347	25,744 Added 8.82%	317,601 $4.76 Million
Q3 2017 Nov 14, 2017	BUY	$12.07 - $14.87 $3.52 Million - $4.34 Million	291,857	291,857 $4.6 Million

Others Institutions Holding IRWD

# of Institutions

247

Shares Held

171M

Call Options Held

11.2M

Put Options Held

28.5K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $714M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account